Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
April 2018
-
Press release
Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments
Hausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto, qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le… -
Press release
Novartis verzeichnet ein starkes erstes Quartal und ergreift Schritte, um ein stärker fokussiertes Arzneimittelunternehmen zu werden
Der Nettoumsatz steigt um 4% (kWk[1], +10% USD), vor allem dank folgender Beiträge: Entresto wächst um 126% (kWk) auf USD 200 Millionen, da es weltweit vermehrt eingesetzt wird Cosentyx legt um… -
Press release
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated… -
Press release
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
The LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials … -
Press release
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and… -
Press release
Novartis bekräftigt Engagement zur Eliminierung von Malaria und investiert USD 100 Millionen in die Erforschung und Entwicklung der nächsten Generation von Malariamedikamenten
Das Unternehmen investiert in den kommenden fünf Jahren über USD 100 Millionen, um die Erforschung und Entwicklung neuer Malariamedikamente voranzutreiben Das Engagement beinhaltet einen Ausbau… -
Press release
Novartis renouvelle son engagement afin d'éliminer le paludisme en investissant 100 millions de dollars dans la recherche et le développement d'antipaludiques de nouvelle génération
L'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'… -
Ad hoc release
Novartis tender offer for AveXis commences
Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has… -
Press release
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE… -
Story Access to Healthcare
Meet Martin Grobusch, malaria fighter
One man’s fascination with malaria helps fuel the search for new treatments.
-
Ad hoc release
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong… -
Ad hoc release
Novartis schliesst Vereinbarung zum Erwerb von AveXis Inc. für USD 8,7 Mrd ab, um Therapie der SMA zu transformieren und Position als führendes Gentherapie-und Neuroscience-Unternehmen auszubauen
Führender Produktkandidat von AveXis, AVXS-101, hat das Potenzial, erste Genersatztherapie zur einmaligen Anwendung zur Behandlung der spinalen Muskelatrophie (SMA) zu werden eine…